Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ASCO 2022 | QoL in response adaptive de-escalated therapy following nivo-based induction in oropharyngeal cancer

Ari Rosenberg, MD, University of Chicago, Chicago, IL, outlines the findings of the investigator-initiated OPTIMA II trial (NCT02258659), which assessed the impact of de-escalated local therapy following anti-PD1 based induction on the quality of life (QoL) of patients with locoregionally advanced human papillomavirus-associated (HPV+) oropharyngeal cancer (OPC). Specifically, during the study, patients were treated with nivolumab with nab-paclitaxel and carboplatin, followed by response adaptive de-intensified treatment. This response adaptive de-escalated treatment regime was found to improve the QoL of patients with locoregionally advanced HPV+ OPC across several domains. This interview took place at the American Society of Clinical Oncology (ASCO) 2022 Annual Meeting in Chicago, IL.

Choose your cookie settings

VJOncology uses necessary cookies to make the site work. With your permission we'd also like to use analytics, preference and marketing cookies to understand how the site is used and improve it.

Choose an option to continue. You can change it at any time on our Cookie Policy page, linked at the bottom of every page.